Bank of New York Mellon
BIVV

Bank of New York Mellon’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Bank of New York Mellon’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,382,422
Closed -$74.5M – 4475
2017
Q4 		$74.5M Buy
1,382,422
+137,792
+11% +$7.54M 0.02% 774
2017
Q3 		$71M Buy
1,244,630
+20,316
+2% +$1.19M 0.02% 773
2017
Q2 		$73.7M Sell
1,224,314
-14,370
-1% -$818K 0.02% 734
2017
Q1 		$67.5M Buy
+1,238,684
New +$61M 0.02% 778

Other funds holding BIVV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
ACS
Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Bank of New York Mellon's BIVV Position: Q1 2018 in Review

Bank of New York Mellon sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 1,382,422 shares — an estimated $74.5M sold.

Bank of New York Mellon first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $74.5M in Q4 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

  • Bank of New York Mellon reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Bank of New York Mellon sold 1,382,422 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $74.5M.
  • Bank of New York Mellon first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
  • Bank of New York Mellon's Bioverativ Inc. Common Stock position peaked at $74.5M in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Bank of New York Mellon's 13F filing for Q1 2018, filed 15 May 2018.